



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1693-F)

#15
2/5/03
82
RECEIVED
JAN 31 2003
PATENT
TECH CENTER 1600/2300

In re Application of:

Fang et al.

Serial No.: 09/895,871 ✓

Filed: June 29, 2001 ✓

For: Compounds to treat Alzheimer's disease ✓

Examiner: Christina Tartera Donnell

Art Unit: 1645

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

VIA HAND DELIVERY

Dear Sir:

This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

1. PCT Application No. WO 99/65870, published December 23, 1999

2. PCT Application No. WO 96/22287, published July 25, 1996.
3. European Patent No 0,432,694, published June, 19, 1991.
4. Chevallier N. et al., Cathepsin D displays in vitro β -secretase-like specificity, Brain Research 750 (1997), pages 11-19
5. Kick E.K. et al., Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D, Chemistry and Biology, April 1997, 4: 297-307.
6. Ng J.S. et al., A practical synthesis of an HIV protease inhibitor intermediate – Diastereoselective epoxide formation from chiral α -aminoaldehydes, Tetrahedron Vol 51, No 23, pages 6397-6410, 1995.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

**McDONNELL BOEHNEN
HULBERT & BERGHOFF**
300 South Wacker Drive, 32nd Floor
Chicago, Illinois 60606
(312) 913-0001

Dated: January 24, 2003

By: 

Steven J. Sarussi
Reg. No. 32,784



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 01-1693-F)

PATENT

RECEIVED

JAN 31 2003

TECH CENTER 1600/2800

In re Application of:

Fang et al.

Serial No.: 09/895,871

Filed: June 29, 2001

For: COMPOUNDS TO TREAT
ALZHEIMER'S DISEASE

Group Art Unit: 1645

Examiner: Christina Tartera Donnell


TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

In regard to the above-identified patent application:

1. We are transmitting herewith the attached:
 - a) Transmittal Letter in Duplicate;
 - b) Supplemental Information Disclosure Statement
 - c) PTO Form 1449; and
 - d) Six Cited References.
2. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayments to the Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
3. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service, with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 24, 2003.

Respectfully submitted,



Steven J. Sarussi
Reg. No. 32,784